New Alzheimer's Drug Candidate Enters Human Trials
The oral treatment aims to address Alzheimer's pathology in a newly launched Phase 1 clinical study.
Updated on Oct. 15, 2026 in Alzheimer’s
Live Poll
Should pharmaceutical research prioritize early disease prevention over the treatment of existing symptoms?
Boston-based Acta Pharmaceuticals has secured $24 million in seed funding to launch a Phase 1 clinical trial for a new Alzheimer's drug candidate, GSM-779690T. The oral, once-daily therapy aims to provide an early intervention option for the 7 million Americans currently living with the disease.
Why it matters
This research targets the biological roots of Alzheimer's by modulating specific proteins linked to the condition's progression. It represents a shift toward early intervention, aiming to intervene before cognitive symptoms become severe.
The Phase 1 trial employs a randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose design to evaluate the candidate in human subjects. While preclinical success has been observed in mini-organoid models, the drug's performance in patients is currently under study.
The players
Acta Pharmaceuticals
A Boston-based biotechnology company focused on developing early-intervention therapies for Alzheimer's disease.
Massachusetts General Hospital
A Boston teaching hospital that licensed intellectual property related to drug combinations to the company.
The details
GSM-779690T functions as a gamma-secretase modulator designed to lower levels of the Aβ42 protein, which is associated with Alzheimer's pathology, while simultaneously boosting Aβ37 and Aβ38 levels. The therapy is delivered as a once-daily oral tablet. Researchers developed the drug using Alzheimer's-in-a-Dish laboratory models, which simulate brain cells in mini-organoids to identify effective treatment combinations.
Timeline
2022: Acta Pharmaceuticals was established.
October 2026: The company initiates its Phase 1 clinical trial for GSM-779690T.
Health Landscape
This study advances the 25-year research effort into gamma-secretase modulation as a strategy for curbing Alzheimer's pathology. It moves beyond traditional approaches by testing specific protein-shifting combinations developed in laboratory organoids.
For those managing Alzheimer's or caring for someone with the condition, this trial represents a new investigational path, though it is not yet a standard treatment option. Discussions regarding clinical trial eligibility should always be held with a neurologist or specialist.
The takeaway
The development of novel protein-modulating drugs offers a potential new avenue for early Alzheimer's intervention. Patients and families can track the progress of such trials through ClinicalTrials.gov to stay informed about the latest research opportunities.
Further reading
For more on the current science of neurodegeneration, visit our section on Alzheimer’s.
More information
You can view the full clinical trial study details on the official registry.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical research prioritize early disease prevention over the treatment of existing symptoms?
